BioMarin Pharmaceutical is set to report its latest earnings this Monday, with analysts anticipating a 4.1% year-over-year revenue growth, significantly slower than the 14.8% increase in the same quarter last year. Despite beating revenue expectations last quarter, the company missed EPS guidance and has struggled with Wall Street’s revenue estimates over the past two years. Investors have shown positive sentiment for the therapeutics segment, although BioMarin’s stock has declined by 3.8% recently, with an average analyst price target of $90.17 compared to its current price of $54.04.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://stockstory.org/us/stocks/nasdaq/bmrn/news/earnings/biomarin-pharmaceutical-bmrn-reports-earnings-tomorrow-what-to-expect
